Meilleure Health International Industry Group Limited reported FY2025 profit attributable to owners of HK$37.98 million, an 18.8% increase from HK$32.48 million a year earlier, despite a 28.0% decline in revenue to HK$36.52 million.

Revenue & Margins • Group revenue fell to HK$36.52 million (FY2024: HK$50.68 million) after sharp contractions in trading (-91.3%) and lower healthcare service income. • Gross profit narrowed 21.8% to HK$22.63 million, yet gross margin improved to 62.0% (FY2024: 57.0%) as the low-margin trading contribution declined.

Segment Performance • Property-related business remained the primary earnings driver, lifting rental income 11.6% to HK$19.20 million; segment profit reached HK$31.88 million (-19.7%). • Healthcare-related revenue slipped 17.9% to HK$16.15 million; segment loss narrowed sharply to HK$4.15 million on lower impairment charges. • Trading revenue plunged to HK$1.17 million, triggering a HK$4.37 million loss (FY2024 profit: HK$7.18 million). • Equity investment activities posted a HK$9.72 million loss versus a HK$15.61 million gain last year, weighed by a HK$12.75 million fair-value loss on financial assets.

Other Key Items • Fair-value gains on investment properties amounted to HK$21.73 million (FY2024: HK$23.81 million). • Other income and gains dropped 52.3% to HK$25.42 million, reflecting decreased fair-value movements of financial instruments. • Finance costs eased 9.7% to HK$9.29 million as borrowing rates moderated in the PRC. • Basic EPS rose to HK0.93 cents (FY2024: HK0.79 cents).

Financial Position • Cash and cash equivalents stood at HK$13.08 million (31 Dec 2024: HK$29.94 million). • Bank borrowings increased to HK$380.40 million; gearing ratio moved to 26.4% (2024: 21.6%). • Net assets edged up 3.9% to HK$1.25 billion, aided by HK$45.53 million of foreign-exchange gains. • Capital commitments contracted to HK$22.90 million (2024: HK$96.19 million).

Dividend The board recommends a final dividend of HK0.4 cents per share, unchanged year-on-year. Together with the interim dividend of HK0.15 cents already paid, total distributions for FY2025 amount to HK0.55 cents per share.

Outlook Management cites supportive national policies, demographic shifts and technological advances as growth catalysts for China’s health sector, positioning the group to deepen its focus on skin health, cell therapy and overseas expansion while pursuing synergistic opportunities and prudent financial management.